KR102246668B1 - 에스트로겐 수용체 조절인자 - Google Patents

에스트로겐 수용체 조절인자 Download PDF

Info

Publication number
KR102246668B1
KR102246668B1 KR1020197025253A KR20197025253A KR102246668B1 KR 102246668 B1 KR102246668 B1 KR 102246668B1 KR 1020197025253 A KR1020197025253 A KR 1020197025253A KR 20197025253 A KR20197025253 A KR 20197025253A KR 102246668 B1 KR102246668 B1 KR 102246668B1
Authority
KR
South Korea
Prior art keywords
compound
formula
methyl
pharmaceutically acceptable
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197025253A
Other languages
English (en)
Korean (ko)
Other versions
KR20190112767A (ko
Inventor
제임스 스튜어트 스콧
토마스 앤드류 모스
사만다 제인 휴스
요하네스 빌헬무스 마리아 니싱크
버나드 크리스토프 바람
빈 양.
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20190112767A publication Critical patent/KR20190112767A/ko
Application granted granted Critical
Publication of KR102246668B1 publication Critical patent/KR102246668B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020197025253A 2017-01-30 2018-01-29 에스트로겐 수용체 조절인자 Active KR102246668B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US62/451,971 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US62/523,695 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US62/560,304 2017-09-19
US201762592485P 2017-11-30 2017-11-30
US62/592,485 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
KR20190112767A KR20190112767A (ko) 2019-10-07
KR102246668B1 true KR102246668B1 (ko) 2021-04-29

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025253A Active KR102246668B1 (ko) 2017-01-30 2018-01-29 에스트로겐 수용체 조절인자

Country Status (35)

Country Link
US (3) US10221173B2 (https=)
EP (2) EP3494116B1 (https=)
JP (1) JP6951451B2 (https=)
KR (1) KR102246668B1 (https=)
CN (1) CN110214140B (https=)
AU (1) AU2018211495B2 (https=)
CL (1) CL2019001991A1 (https=)
CO (1) CO2019008941A2 (https=)
CR (1) CR20190379A (https=)
CY (1) CY1122731T1 (https=)
DK (1) DK3494116T3 (https=)
DO (1) DOP2019000183A (https=)
EC (1) ECSP19062381A (https=)
ES (2) ES2766249T3 (https=)
HU (1) HUE047761T2 (https=)
IL (1) IL268263B (https=)
JO (1) JOP20190183B1 (https=)
LT (1) LT3494116T (https=)
MA (1) MA52555A (https=)
MX (1) MX2019008438A (https=)
MY (1) MY196317A (https=)
NI (1) NI201900080A (https=)
PE (1) PE20191500A1 (https=)
PH (1) PH12019501724A1 (https=)
PL (1) PL3494116T3 (https=)
PT (1) PT3494116T (https=)
RS (1) RS59770B1 (https=)
SG (1) SG11201906767XA (https=)
SI (1) SI3494116T1 (https=)
SM (1) SMT202000010T1 (https=)
TN (1) TN2020000009A1 (https=)
TW (1) TWI794205B (https=)
UA (1) UA125043C2 (https=)
WO (1) WO2018138303A1 (https=)
ZA (1) ZA201904696B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138758A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
US20140357661A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
US20160175289A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180021316A1 (en) 2016-07-25 2018-01-25 Astrazeneca Ab Chemical compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
EP1746157A4 (en) * 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd PROCESS FOR PLASMA CELL PROGRAMMING
WO2006101434A1 (en) 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
US10087191B2 (en) 2015-06-16 2018-10-02 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
HK1258851A1 (zh) 2015-11-09 2019-11-22 豪夫迈‧罗氏有限公司 四氢萘雌激素受体调节剂及其用途
JP6592197B2 (ja) 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
CA3006683A1 (en) 2015-12-22 2017-06-29 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
US20190233442A1 (en) 2016-05-06 2019-08-01 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
EP3640251B1 (en) 2016-10-24 2021-12-08 Astrazeneca AB 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
ES2941631T3 (es) 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
EP3555050A1 (en) 2016-12-16 2019-10-23 Basf Se Pesticidal compounds
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
GEP20207202B (en) 2017-01-30 2020-12-25 Chiesi Farm Spa Tyrosine amide derivatives as rho-kinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138758A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
US20140357661A1 (en) 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
US20160175289A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180021316A1 (en) 2016-07-25 2018-01-25 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
PT3494116T (pt) 2020-01-28
MY196317A (en) 2023-03-24
EP3689873A1 (en) 2020-08-05
JOP20190183A1 (ar) 2019-07-28
DK3494116T3 (da) 2020-01-27
TN2020000009A1 (en) 2021-10-04
PE20191500A1 (es) 2019-10-22
HUE047761T2 (hu) 2020-05-28
TWI794205B (zh) 2023-03-01
CA3050337A1 (en) 2018-08-02
CO2019008941A2 (es) 2019-08-30
WO2018138303A1 (en) 2018-08-02
PH12019501724A1 (en) 2020-06-01
US20190233413A1 (en) 2019-08-01
CR20190379A (es) 2019-10-21
IL268263B (en) 2021-10-31
ECSP19062381A (es) 2019-09-30
RS59770B1 (sr) 2020-02-28
US11046689B2 (en) 2021-06-29
CY1122731T1 (el) 2021-05-05
CN110214140A (zh) 2019-09-06
TW201840558A (zh) 2018-11-16
US20200239468A1 (en) 2020-07-30
NI201900080A (es) 2020-03-18
ZA201904696B (en) 2020-05-27
BR112019015389A2 (pt) 2020-03-10
US10221173B2 (en) 2019-03-05
US10590132B2 (en) 2020-03-17
EP3689873B1 (en) 2022-09-14
ES2766249T3 (es) 2020-06-12
JP2020505354A (ja) 2020-02-20
IL268263A (en) 2019-09-26
ES2931320T3 (es) 2022-12-28
SMT202000010T1 (it) 2020-03-13
JP6951451B2 (ja) 2021-10-20
KR20190112767A (ko) 2019-10-07
US20180282325A1 (en) 2018-10-04
AU2018211495A1 (en) 2019-09-12
SI3494116T1 (sl) 2020-02-28
EP3494116A1 (en) 2019-06-12
JOP20190183B1 (ar) 2022-09-15
UA125043C2 (uk) 2021-12-29
EP3494116B1 (en) 2019-10-23
SG11201906767XA (en) 2019-08-27
DOP2019000183A (es) 2019-07-31
MX2019008438A (es) 2019-10-30
LT3494116T (lt) 2020-01-10
MA52555A (fr) 2021-03-17
PL3494116T3 (pl) 2020-04-30
CN110214140B (zh) 2022-08-30
CL2019001991A1 (es) 2019-10-11
AU2018211495B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
US12077530B2 (en) Chemical compounds
KR102246668B1 (ko) 에스트로겐 수용체 조절인자
US10149839B2 (en) Chemical compounds
US10125135B2 (en) Chemical compounds
CA3050337C (en) 1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indole compounds as estrogen receptor modulators
HK40007252B (en) Estrogen receptor modulators
HK40007252A (en) Estrogen receptor modulators
EA038160B1 (ru) Модуляторы рецептора эстрогена
BR112019015389B1 (pt) Composto ácido (r)-3-((1r,3r)-1-(5-fluoro-2-(2-((3- fluoropropil)amino) etóxi)-3-metilpiridin-4-il)-3-metil1,3,4,9-tetra-hidro-2h-pirido[3,4-b]indol-2-il)-2- metilpropanoico, composição farmacêutica e uso do composto para tratamento de cancer de mama ou ginecológico
EA037533B1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6